Non-Small Cell Lung Cancer (NSCLC)

Part of Respiratory diseases

🏥3Companies

❤️1Engagements

Companies in Non-Small Cell Lung Cancer (NSCLC)

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Schrödinger

IPO

New York, New York, USA

Schrödinger is an international scientific software and biotechnology company, founded in 1990, developing computational tools for drug discovery and materials science. Its phys...

...more

Business ModelB2B (Software licensing) and a drug discovery model, advancing preclinical and clinical programs internally and through collaborations. SaaS is implied through platform licensing.

Core Techphysics-based computational platform

Funding$394.2M

Founded1990

Drug Discovery/Development

57

Get Involved in Schrödinger

O

Oxford BioTherapeutics

Unknown

Oxford, CA, UK

Oxford BioTherapeutics (OBT) is a clinical-stage oncology company based in Oxford, UK, and San Jose, USA. It is dedicated to discovering and developing first-in-class antibody-b...

...more

Business ModelB2B

Core TechProprietary proteomic target discovery platform called OG...

Funding$14.6M

Drug Discovery/Development

32

Get Involved in Oxford BioTherapeutics

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

A

AstraZeneca

IPO

Cambridge, UK

AstraZeneca is a pharmaceutical company engaged in multi-year AI-powered drug discovery collaborations to identify validated targets in various disease areas.

...more

Business ModelPharmaceutical R&D, manufacturing, and commercialization of prescription medicines, primarily generating revenue through product sales, licensing agreements, royalties, and milestone payments from partnerships.

Core TechAI-powered drug discovery

Founded1999

Drug Discovery/Development

26

Get Involved in AstraZeneca